AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
SciSparc shares surge 28.28% premarket after acquiring MUSE endoscopy IP targeting $3.03B GERD market.
ByAinvest
Wednesday, Nov 26, 2025 7:56 am ET1min read
SciSparc (SPRC) surged 28.28% in premarket trading following the announcement of a binding term sheet to acquire a portfolio of patents, trademarks, and intellectual property for the MUSE™ endoscopic system from Xylo Technologies. The MUSE™ system, designed for minimally invasive GERD treatment, grants SciSparc access to a market projected to grow from $2.5 billion in 2024 to $3.03 billion by 2030. The transaction involves issuing 19.99% of SciSparc’s shares to Xylo, leveraging Xylo’s prior commercialization success in China, where it secured a $3 million upfront payment in 2019. The deal aligns with SciSparc’s strategy to expand into high-growth regions via regional partnerships, positioning the company to capitalize on the expanding GERD device market.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet